JENNA LASKOSKI: Open Payments
NPI 1316609209 · GILBERT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$422 in 19 payments from 10 companies in 2025. Trend: 2023 $91 · 2024 $1,092 · 2025 $422
Food & beverage: $422
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 6 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| PFIZER INC. | 2 | $52 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| ABBVIE INC. | 2 | $32 |
| Mauna Kea Technologies, Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Boston Scientific Corporation | 1 | $27 |
| Janssen Biotech, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $18 |
Products named: ENTYVIO, LINZESS, ZENPEP, General - Pain Management, XELJANZ, TREMFYA, VELSIPITY, RELISTOR.
Industry payments across AZ — which companies pay providers there.
